These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9746032)

  • 1. Relief by botulinum toxin of voiding dysfunction due to prostatitis.
    Maria G; Destito A; Lacquaniti S; Bentivoglio AR; Brisinda G; Albanese A
    Lancet; 1998 Aug; 352(9128):625. PubMed ID: 9746032
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: intradetrusor botulinum neurotoxin A (BoNT-A) injections decrease bladder fibrosis secondary to partial urethral obstruction in the male rat model. Neurourol urodyn 2012;31:564-70.
    Pascali MP; De Gennaro M; Mosiello G
    Neurourol Urodyn; 2012 Apr; 31(4):571. PubMed ID: 22275177
    [No Abstract]   [Full Text] [Related]  

  • 3. Botox injections may ease men's urinary woes.
    Health News; 2003 Nov; 9(11):15. PubMed ID: 14619824
    [No Abstract]   [Full Text] [Related]  

  • 4. Botulinum toxin type A vs type B for axillary hyperhidrosis in a case series of patients observed for 6 months.
    Frasson E; Brigo F; Acler M; Didonè G; Vicentini S; Bertolasi L
    Arch Dermatol; 2011 Jan; 147(1):122-3. PubMed ID: 21242408
    [No Abstract]   [Full Text] [Related]  

  • 5. A review of botulinum toxin use for chronic pelvic pain syndrome.
    Gottsch HP; Yang CC; Berger RE
    Curr Urol Rep; 2010 Jul; 11(4):265-70. PubMed ID: 20446070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intradetrusor botulinum neurotoxin A (BoNT-A) injections decrease bladder fibrosis secondary to partial urethral obstruction in the male rat model.
    Tinay I; Tanidir Y; Cikler E; Cetinel S; Tarcan T
    Neurourol Urodyn; 2012 Apr; 31(4):564-70. PubMed ID: 22275224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [First experience of using lantox (botulinum toxin A) in chronic pelvic pain syndrome combined with bladder emptying dysfunction].
    Krivoborodov GG; Shumilo DV; Vasil'ev AV
    Urologiia; 2010; (2):60-2. PubMed ID: 20973143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Botulinum A toxin treatment of urethral sphincter pseudodyssynergia in patients with cerebrovascular accidents or intracranial lesions.
    Chen YH; Kuo HC
    Urol Int; 2004; 73(2):156-61; discussion 161-2. PubMed ID: 15331901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum toxin for urogenital conditions.
    Eccleston KJ; Woolley PD
    Int J STD AIDS; 2008 Dec; 19(12):797-9. PubMed ID: 19050206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful botulinum toxin (onabotulinumtoxinA) treatment of Hailey-Hailey disease.
    Ho D; Jagdeo J
    J Drugs Dermatol; 2015 Jan; 14(1):68-70. PubMed ID: 25607910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum Toxin A in bruxers. One year experience.
    Redaelli A
    Saudi Med J; 2011 Feb; 32(2):156-8. PubMed ID: 21301762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum toxin for depression: Does patient appearance matter?
    Reichenberg JS; Hauptman AJ; Robertson HT; Finzi E; Kruger TH; Wollmer MA; Magid M
    J Am Acad Dermatol; 2016 Jan; 74(1):171-173.e1. PubMed ID: 26702796
    [No Abstract]   [Full Text] [Related]  

  • 13. Successful treatment of vulvodynia with botulinum toxin A.
    Tieu KD; MacGregor JL
    Arch Dermatol; 2011 Feb; 147(2):251-2. PubMed ID: 21339463
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term efficacy and durability of botulinum-A toxin for refractory dysfunctional voiding in children.
    Vricella GJ; Campigotto M; Coplen DE; Traxel EJ; Austin PF
    J Urol; 2014 May; 191(5 Suppl):1586-91. PubMed ID: 24679879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of facial myokymia in multiple sclerosis with botulinum toxin.
    Habek M; Adamec I; Gabelić T; Brinar VV
    Acta Neurol Belg; 2012 Dec; 112(4):423-4. PubMed ID: 22669610
    [No Abstract]   [Full Text] [Related]  

  • 16. Botulinum toxin A in anti-GAD-positive stiff-limb syndrome.
    Anagnostou E; Zambelis T
    Muscle Nerve; 2012 Sep; 46(3):457-8. PubMed ID: 22907242
    [No Abstract]   [Full Text] [Related]  

  • 17. Botulinum toxin type A in the management of a neuropathic foot ulcer.
    Alsharqi A; Curley R; Winhoven S
    Clin Exp Dermatol; 2011 Dec; 36(8):915-6. PubMed ID: 21623883
    [No Abstract]   [Full Text] [Related]  

  • 18. Botulinum toxin type A and type B for sialorrhoea in Parkinson's disease: a case for switching therapy?
    Santamato A; Panza F; Solfrizzi V; Frisardi V; Ranieri M; Fiore P
    J Rehabil Med; 2008 Nov; 40(10):882-3. PubMed ID: 19242630
    [No Abstract]   [Full Text] [Related]  

  • 19. Prophylactic botulinum type A toxin complex (Dysport®) for migraine without aura.
    Chankrachang S; Arayawichanont A; Poungvarin N; Nidhinandana S; Boonkongchuen P; Towanabut S; Sithinamsuwan P; Kongsaengdao S
    Headache; 2011 Jan; 51(1):52-63. PubMed ID: 21083558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The use of botulinum toxin type A in masseter muscle hypertrophy: long-term effects and lasting improvement].
    Aydil B; Başaran B; Unsaler S; Süoğlu Y
    Kulak Burun Bogaz Ihtis Derg; 2012; 22(5):249-53. PubMed ID: 22991984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.